CL2020003447A1 - Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas - Google Patents

Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas

Info

Publication number
CL2020003447A1
CL2020003447A1 CL2020003447A CL2020003447A CL2020003447A1 CL 2020003447 A1 CL2020003447 A1 CL 2020003447A1 CL 2020003447 A CL2020003447 A CL 2020003447A CL 2020003447 A CL2020003447 A CL 2020003447A CL 2020003447 A1 CL2020003447 A1 CL 2020003447A1
Authority
CL
Chile
Prior art keywords
compositions
methods
inflammasome
conditions
related diseases
Prior art date
Application number
CL2020003447A
Other languages
English (en)
Spanish (es)
Inventor
Robert W Keane
W Dalton Dietrich
Rivero Vaccari Juan Pablo De
Helen M Bramlett
Roberta Brambilla
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/026,482 external-priority patent/US10703811B2/en
Application filed by Univ Miami filed Critical Univ Miami
Publication of CL2020003447A1 publication Critical patent/CL2020003447A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CL2020003447A 2018-07-03 2020-12-30 Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas CL2020003447A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/026,482 US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
CL2020003447A1 true CL2020003447A1 (es) 2021-07-30

Family

ID=78823964

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003447A CL2020003447A1 (es) 2018-07-03 2020-12-30 Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas

Country Status (16)

Country Link
US (1) US20210284723A1 (enExample)
EP (1) EP3818081A4 (enExample)
JP (2) JP2021528092A (enExample)
KR (1) KR20210071944A (enExample)
CN (1) CN113316588B (enExample)
AU (1) AU2019297515A1 (enExample)
BR (1) BR112020026798A2 (enExample)
CA (1) CA3105129A1 (enExample)
CL (1) CL2020003447A1 (enExample)
CO (1) CO2021001172A2 (enExample)
IL (1) IL279851A (enExample)
MX (1) MX2021000142A (enExample)
PH (1) PH12020552286A1 (enExample)
SG (1) SG11202013176VA (enExample)
WO (1) WO2020010273A1 (enExample)
ZA (2) ZA202100703B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222263A2 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
JP2024544997A (ja) * 2021-11-16 2024-12-05 エイシー イミューン ソシエテ アノニム 治療および診断のための新規分子
CA3267095A1 (en) * 2022-09-09 2024-03-14 University Of Miami Composition of anti-inflammatory antibodies and method of treating a neurological disorder
WO2024114906A1 (en) * 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
WO2005111283A1 (ja) * 2004-05-17 2005-11-24 Denki Kagaku Kogyo Kabushiki Kaisha ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪
NZ554725A (en) * 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
RU2009135824A (ru) * 2007-02-27 2011-04-10 Дженентек, Инк. (Us) Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
WO2010003092A1 (en) * 2008-07-03 2010-01-07 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
JP5976695B2 (ja) * 2011-03-11 2016-08-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 慢性閉塞性肺疾患（ｃｏｐｄ）のマーカーとしてのａｓｃ
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
WO2015016178A1 (ja) * 2013-07-29 2015-02-05 国立大学法人鹿児島大学 １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
KR101948048B1 (ko) * 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
US11840565B2 (en) * 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
WO2018126009A1 (en) * 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung

Also Published As

Publication number Publication date
PH12020552286A1 (en) 2021-06-21
WO2020010273A1 (en) 2020-01-09
CO2021001172A2 (es) 2021-07-09
CN113316588B (zh) 2025-02-28
IL279851A (en) 2021-03-01
EP3818081A1 (en) 2021-05-12
KR20210071944A (ko) 2021-06-16
CN113316588A (zh) 2021-08-27
US20210284723A1 (en) 2021-09-16
ZA202201437B (en) 2024-05-30
BR112020026798A2 (pt) 2021-03-30
JP2025067915A (ja) 2025-04-24
CA3105129A1 (en) 2020-01-09
MX2021000142A (es) 2021-05-12
EP3818081A4 (en) 2022-06-22
AU2019297515A1 (en) 2021-02-25
SG11202013176VA (en) 2021-01-28
JP2021528092A (ja) 2021-10-21
ZA202100703B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
CO2022010241A2 (es) Inhibidores de sos1
CO2019008087A2 (es) Método para modular la actividad de inflamasoma e inflamación en el pulmón
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
MX2021009673A (es) Moduladores de ror-gamma.
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
CL2020002019A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2019002371A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
UY37391A (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY37098A (es) Moduladores de ror-gamma
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
CL2021001027A1 (es) Inhibidores selectivos de rgmc y el uso de los mismos
MX2017014818A (es) Agonistas de triazol del receptor apj.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
PE20180691A1 (es) Variantes de il-37
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX2021002294A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.